Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (NCT07849660) titled 'Real-World Lenvatinib Sequencing in Unresectable Hepatocellular Carcinoma (uHCC)' on Sept. 24.

Study Type: Observational

Primary Sponsor: Eisai Inc.

Condition: Carcinoma, Hepatocellular

Intervention: Drug: Lenvatinib

Recruitment Status: Not recruiting

Date of First Enrollment: November 17, 2025

Target Sample Size: 170

Countries of Recruitment: United States

To know more, visit https://clinicaltrials.gov/study/NCT07849660

Published by HT Digital Content Services with permission from Health Daily Digest....